NK and TIL Cell Expansion Reagents (K562 Feeder Cells)

 

NK and TIL Cell Expansion Reagents (K562 Feeder Cells)

Hillgene's NK and TIL Cell Expansion Reagent (Feeder cell) is an irradiated and inactivated engineered k562 cells expressing IL-21 and other cytokines, which, together with the mainstream immune cell culture medium, can activate and expand NK cells and tumor-infiltrating TIL cells derived from umbilical cord blood and peripheral blood mononuclear cells cultured in vitro, and the purity of the obtained NK and TIL cells is high.

 

Features of NK and TIL Cell Expansion Reagents (K562 Feeder Cells)

Reliability

Reliable NK,TIL expansion using K562 feeder system

 

Results

NK and TIL expansion reagents with K562 feeder

 

Efficiency

K562 feeder reagents for efficient NK and TIL growth

 

NK Cell Preparation Flowchart

D0: Plasma and PBMC isolation, inoculation and activation

 

D4: Observe and medium exchange

 

D6: Observe and medium infusion

 

D8: Observe and medium infusion, re-activation

 

D10: Observe and medium exchange

 

D12: Observe and medium infusion

 

D14: Harvest

 

Application of NK and TIL Cell Expansion Reagents (K562 Feeder Cell)

Suitable for activation and mass expansion of different immune cells such as NK cells, CAR-NK cells and TIL.

 

Process Development Stage: Evaluate the in vitro expansion capacity of cells such as NK and TIL and optimize the process during the early development stage of cell therapy products.

 

Process locking, product production and comparability study phase: During the mid-term process locking, production and cell process change phase after IND approval for cell therapy products, establish stable cell expansion processes based on trophoblast cells, such as NK and TIL, and carry out process locking, cellular drug production and comparability studies for cell products.

 

Hillgene provides full-service CDMO solutions for CAR-T, CAR-NK, and TCR-T therapies, supporting your journey from research to GMP manufacturing and beyond. As a specialized cell therapy biopharma CDMO, we offer expertise in CAR-T manufacturing, viral vector production, and regulatory support. Our agile team helps biotechs accelerate development with flexible, scalable, and compliant processes. Whether you're entering clinical trials or preparing for commercialization, our customized approach ensures speed, quality, and reliability at every stage. Partner with us to bring your next-generation therapies to life, faster and smarter.

 

评论

此博客中的热门博文

HiPlas™ LentiHelper Plasmids for T

Proprietary Products

Trusted Cell Therapy CDMO